Invention Grant
US08475842B2 Immediate release pharmaceutical formulation of 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one
有权
4- [3-（4-环丙基羰基 - 哌嗪-1-羰基）-4-氟 - 苄基] -2H-酞嗪-1-酮的立即释放药物制剂
![Immediate release pharmaceutical formulation of 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one](/docs/US/2013-07-02/US08475842B2/abs.jpg.600x600.jpg)
- Patent Title: Immediate release pharmaceutical formulation of 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one
- Patent Title (中): 4- [3-（4-环丙基羰基 - 哌嗪-1-羰基）-4-氟 - 苄基] -2H-酞嗪-1-酮的立即释放药物制剂
-
Application No.: US12574801Application Date: 2009-10-07
-
Publication No.: US08475842B2Publication Date: 2013-07-02
- Inventor: Michael Karl Bechtold , Claudia Bettina Packhaeuser , Katja Maren Fastnacht , Bernd Harald Liepold , Benedikt Steitz , Julie Kay Cahill , Kieran James Lennon
- Applicant: Michael Karl Bechtold , Claudia Bettina Packhaeuser , Katja Maren Fastnacht , Bernd Harald Liepold , Benedikt Steitz , Julie Kay Cahill , Kieran James Lennon
- Applicant Address: SE Sodertalje
- Assignee: Astrazeneca AB
- Current Assignee: Astrazeneca AB
- Current Assignee Address: SE Sodertalje
- Agency: Astrazeneca AB
- Main IPC: A61K9/10
- IPC: A61K9/10 ; A61K9/20 ; A61K31/502 ; A61P35/00
![Immediate release pharmaceutical formulation of 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one](/abs-image/US/2013/07/02/US08475842B2/abs.jpg.150x150.jpg)
Abstract:
The present invention relates to a pharmaceutical formulation comprising the drug 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one in a solid dispersion with a matrix polymer that exhibits low hygroscopicity and high softening temperature, such as copovidone. The invention also relates to a daily pharmaceutical dose of the drug provided by such a formulation. In addition, the invention relates to the use of a matrix polymer that exhibits low hygroscopicity and high softening temperature in solid dispersion with 4-[3-(4-cyclopropanecarbonyl-piperazine-1 -carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one for increasing the bioavailability of the drug.
Public/Granted literature
- US20100098763A1 PHARMACEUTICAL FORMULATION 514 Public/Granted day:2010-04-22
Information query
